← Leaderboards
Gary Fujii
Molecular Express, Inc.
$24,455,077
Attributed
$24,455,077
Total exposure
35
Grants
31
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,455,077 · 35
By mechanism
R44$11,953,491 · 5
R43$6,633,530 · 19
U01$2,388,206 · 1
N43$1,067,473 · 3
N01$737,219 · 2
R41$667,746 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseProteinsSmall Business Innovation Research GrantLiposomesTechnologyAnimalsDesignImmune ResponseVaccinesLipidsMolecularAntigensProductionPublic Health RelevanceMonitorProceduresInfectionResponseVaccine DevelopmentLaboratoriesImmunizationDosePreparationEngineering
Grant awards (54)
Preclinical Development of a ME-1001, a Synthetic Lung Surfactant$999,784
R44 · FY2025 · HL · contact PI
Project 1 - VesiVax®-adjuvanted cocktail vaccine formulation against Neisseria gonorrhoeae (CIIG)$582,458
U19 · FY2025 · AI · contact PI
Preclinical Development of a ME-1001, a Synthetic Lung Surfactant$999,853
R44 · FY2024 · HL · contact PI
VesiVax Vaccine Formulation Against Neisseria gonorrhoeae$299,779
R43 · FY2023 · AI · contact PI
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS$1,031,789
R44 · FY2022 · HL · contact PI
VesiVax Vaccine Formulation Against Neisseria gonorrhoeae$299,817
R43 · FY2022 · AI · contact PI
Niclosamide Formulations for the Treatment of Influenza Infections$298,479
R43 · FY2022 · AI · contact PI
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS$113,400
R44 · FY2022 · HL · contact PI
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS$67,200
R44 · FY2022 · HL · contact PI
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS$956,889
R44 · FY2021 · HL · contact PI
DEVELOPMENT OF A VESIVAS IMMUNOSIMILAR FORMULATION$569,807
N43 · FY2021 · AI · contact PI
Design and Engineering of VesiVax HIV Immunogen Formulations$299,993
N43 · FY2020 · AI · contact PI
Development of a Vaccine for the Prevention of Pulmonary Aspergillosis$497,338
R44 · FY2018 · AI · contact PI
Development of a Vaccine for the Prevention of Pulmonary Aspergillosis$934,456
R44 · FY2017 · AI · contact PI
VesiVax® Peanut Allergy Immunotherapy$300,000
R43 · FY2017 · AI · contact PI
DELIVERY OF SELF-REPLICATING HIV VACCINES USING IN VITRO RECONSTITUTED VIRUS-LIKE PARTICLES$296,286
N01 · FY2017 · AI · contact PI
DEVELOPMENT OF A WEST NILE VIRUS VACCINE$440,933
N01 · FY2016 · AI · contact PI
Optimization of VesiVax® Lipidated Tucaresol Formulations$225,000
R43 · FY2016 · AI · contact PI
Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction$95,143
R42 · FY2016 · DA · contact PI
Development of a Gene and Oligonucleotide Delivery System$322,946
R41 · FY2015 · TR · contact PI
Design and Engineering of Nanoparticulate Universal Vaccines$290,263
R43 · FY2015 · AI · contact PI
Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction$225,033
R42 · FY2015 · DA · contact PI
Development of a novel SP-B peptide lung surfactant$1,051,147
R44 · FY2014 · HL · contact PI
Novel VLP Adjuvant based on the VesiVax system$299,999
R43 · FY2014 · AI · contact PI
Engineering of a Novel CDN Nanoparticle Platform$245,943
R43 · FY2014 · AI · contact PI
Development of a novel SP-B peptide lung surfactant$957,467
R44 · FY2013 · HL · contact PI
Novel VLP Adjuvant based on the VesiVax system$299,999
R43 · FY2013 · AI · contact PI
Development of VesiVax Carbohydrate Conjugation Chemistry$294,301
R43 · FY2013 · AI · contact PI
Development of a novel SP-B peptide lung surfactant$953,604
R44 · FY2012 · HL · contact PI
Liposomal Nicotine Vaccine Development$344,800
R41 · FY2011 · DA · contact PI
DEVELOPMENT OF A COMMERCIAL POINT-OF-CARE DEVICE CAPABLE OF ELECTRONICALLY SENSI$197,673
N43 · FY2011 · CA · contact PI
ENDPOINTS FOR CORRELATING PROTECTIVE IMMUNITY IN RESPONSE TO INFLUENZA$104,778
P51 · FY2011 · RR · contact PI
Surrogate endpoints for correlating protective immunity in response to influenza$299,994
R43 · FY2010 · AI · contact PI
Genital Herpes Vaccine Discovery$197,977
R44 · FY2010 · AI · contact PI
Genital Herpes Vaccine Discovery$989,544
R44 · FY2009 · AI · contact PI
Production of a Lung Surfactant SP-B Mimic$625,381
R44 · FY2009 · HL · contact PI
Surrogate endpoints for correlating protective immunity in response to influenza$300,000
R43 · FY2009 · AI · contact PI
Virus Electrodes for Fungal Pathogen Detection$62,430
R43 · FY2009 · AI · contact PI
Non-Viral Pandemic Influenza Vaccine Development$1,001,081
U01 · FY2008 · AI · contact PI
Genital Herpes Vaccine Discovery$992,626
R44 · FY2008 · AI · contact PI
Production of a Lung Surfactant SP-B Mimic$585,036
R44 · FY2008 · HL · contact PI
Development of an Aspergillus Vaccine$300,001
R43 · FY2008 · AI · contact PI
Virus Electrodes for Fungal Pathogen Detection$300,000
R43 · FY2008 · AI · contact PI
Thermal Targeting of Antimicrobial Drugs to Sites of Infection$300,000
R43 · FY2008 · AI · contact PI
Liposomal Adjuvant for Vaccine Development$299,985
R43 · FY2008 · AI · contact PI
Non-Viral Pandemic Influenza Vaccine Development$1,387,125
U01 · FY2007 · AI · contact PI
Genital Herpes Vaccine Discovery$380,244
R43 · FY2007 · AI · contact PI
Development of an Aspergillus Vaccine$299,999
R43 · FY2007 · AI · contact PI
Genital Herpes Vaccine Discovery$374,532
R43 · FY2006 · AI · contact PI
Selection and Characterization of PSMA Ligands from Phage-Displayed Libraries$335,955
R43 · FY2006 · CA · contact PI
Production of a Lung Surfactant SP-B Mimic$138,000
R43 · FY2005 · HL
Rapid Vaccine Development System$131,960
R43 · FY2002 · AI
TARGETED LIPOSOMAL DRUG DELIVERY TO LEUKEMIA CELLS$156,850
R43 · FY2001 · CA
DESIGN AND ENGINEERING OF A TARGETED LIPOSOME SYSTEM$100,000
R43 · FY2000 · CA